Literature DB >> 23167743

New in silico and conventional in vitro approaches to advance HIV drug discovery and design.

Giovanni Maga1, Nevena Veljkovic, Emmanuele Crespan, Silvio Spadari, Jelena Prljic, Vladimir Perovic, Sanja Glisic, Veljko Veljkovic.   

Abstract

INTRODUCTION: Recently, the new concept of the long-range intermolecular interactions in biological systems has been proposed. Combined use of molecular modeling techniques and the screening techniques based on the long-range interaction concept could significantly improve and accelerate discovery of new HIV drugs. However, any hit identified in silico needs to be characterized with respect to its biological target by enzymatic studies. Combined use of the in silico screening and the enzymatic studies allows an efficient selection of new anti-HIV drugs. AREAS COVERED: The focus of this article is on the in silico screening of molecular libraries for candidate new HIV drugs, which is based on the molecular descriptors determining the long-range interaction between the drugs and their therapeutic target. This article also reviews the techniques for enzyme kinetic studies which are required for optimization of in silico selected candidate anti-HIV drugs. EXPERT OPINION: The novel approach of combining in silico screening techniques with enzymatic studies enables the accurate measurement of the quantitative descriptors of ligand-enzyme interactions. This novel method is a powerful tool for new anti-HIV drug discovery which can also reduce the drug development costs.

Mesh:

Substances:

Year:  2012        PMID: 23167743     DOI: 10.1517/17460441.2013.741118

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  2 in total

1.  In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.

Authors:  Veljko Veljkovic; Marco Goeijenbier; Sanja Glisic; Nevena Veljkovic; Vladimir R Perovic; Milan Sencanski; Donald R Branch; Slobodan Paessler
Journal:  F1000Res       Date:  2015-05-01

2.  Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection.

Authors:  Veljko Veljkovic; Philippe M Loiseau; Bruno Figadere; Sanja Glisic; Nevena Veljkovic; Vladimir R Perovic; David P Cavanaugh; Donald R Branch
Journal:  F1000Res       Date:  2015-02-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.